ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025
Clinical outcomes of the PAUL Glaucoma implant for neovascular glaucoma.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn neovascular glaucoma (NVG), surgical interventions such as glaucoma drainage devices (GDD), may become necessary, especially when other therapies prove ineffective. The PAUL® Glaucoma Implant (PGI), with its refined, smaller drainage tube, presents a promising solution for lowering intraocular pressure (IOP) in such complex cases. This study aims to evaluate the PGI's effectiveness and safety in managing IOP in patients with NVG.
methodsThis study reviewed medical records of patients who underwent PGI surgery for NVG at the University Hospital Bonn between May 2021 and January 2024. Preoperative and follow-up data, including IOP, BCVA, visual field progression, and complications, were collected prospectively. Success was defined using four IOP-based criteria (≤ 21, ≤ 18, ≤ 15, and ≤ 12 mmHg) per World Glaucoma Association (WGA) guidelines (World Glaucoma Association et al. 2009). Outcomes were classified as complete (without medication) or qualified (with or without medication). Failure included hypotony-related complications, need for further surgery, or PGI explantation. The primary endpoint was success rate by IOP criteria; secondary endpoints included changes in IOP, BCVA, medication use, complications, and impact of Prolene stent removal.
resultsThe study analyzed 23 eyes from 22 patients undergoing PGI surgery, with the majority being male (60.9%) and Caucasian (95.7%), and with an average age of 65.2 years. Success rates were highest for IOP ≤ 21 mmHg (60%-80% at 12 months) and declined with stricter thresholds, with only 10% maintaining IOP ≤ 12 mmHg. Prior to surgery, the mean intraocular pressure (IOP) was 27.22 mmHg. Following the procedure, a substantial reduction was observed, with IOP decreasing to 12.95 mmHg at the 12-month follow-up-representing an average decrease of 53.1%.
conclusionThe PGI demonstrates significant IOP reduction in NVG, with sustained success at higher IOP thresholds. However, maintaining very low IOP levels remains challenging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.